TScan Therapeutics (NASDAQ:TCRX) Receives “Buy” Rating from HC Wainwright

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $15.00 target price on the stock.

TCRX has been the topic of several other reports. Wedbush reiterated an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a research note on Wednesday. Needham & Company LLC cut their target price on TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday.

TScan Therapeutics Price Performance

TCRX stock opened at $1.92 on Thursday. The business’s 50-day moving average is $2.45 and its two-hundred day moving average is $4.06. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics has a 1 year low of $1.82 and a 1 year high of $9.69. The firm has a market capitalization of $102.47 million, a P/E ratio of -1.81 and a beta of 0.87.

TScan Therapeutics (NASDAQ:TCRX) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. Analysts anticipate that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Checkpoint Capital L.P. purchased a new stake in TScan Therapeutics during the 3rd quarter valued at approximately $4,110,000. abrdn plc increased its stake in TScan Therapeutics by 137.8% in the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock valued at $2,686,000 after buying an additional 512,049 shares during the period. State Street Corp lifted its position in TScan Therapeutics by 24.4% in the third quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after purchasing an additional 148,414 shares during the period. Dimensional Fund Advisors LP lifted its holdings in TScan Therapeutics by 108.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock valued at $851,000 after acquiring an additional 145,731 shares during the period. Finally, Lynx1 Capital Management LP lifted its position in shares of TScan Therapeutics by 2.5% during the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock valued at $16,286,000 after acquiring an additional 132,747 shares during the period. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.